Assetmark Inc. Sells 39,781 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Assetmark Inc. trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 24.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,087 shares of the biopharmaceutical company’s stock after selling 39,781 shares during the period. Assetmark Inc.’s holdings in Amicus Therapeutics were worth $1,283,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC raised its holdings in Amicus Therapeutics by 20.1% in the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock valued at $162,713,000 after acquiring an additional 2,307,385 shares in the last quarter. William Blair Investment Management LLC raised its stake in Amicus Therapeutics by 12.8% in the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after purchasing an additional 1,477,084 shares in the last quarter. Fiera Capital Corp lifted its position in Amicus Therapeutics by 1.1% during the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after purchasing an additional 58,113 shares during the period. Massachusetts Financial Services Co. MA grew its stake in Amicus Therapeutics by 14.3% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,020,536 shares of the biopharmaceutical company’s stock worth $29,964,000 after buying an additional 378,999 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Amicus Therapeutics by 17.9% in the 2nd quarter. Victory Capital Management Inc. now owns 2,273,959 shares of the biopharmaceutical company’s stock valued at $22,558,000 after buying an additional 345,117 shares during the period.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,901 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. This represents a 0.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 30,401 shares of company stock valued at $352,038 over the last three months. Corporate insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Performance

FOLD opened at $10.09 on Friday. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57. The company has a market cap of $3.01 billion, a price-to-earnings ratio of -29.68 and a beta of 0.68. The company’s fifty day moving average price is $11.04 and its two-hundred day moving average price is $10.61. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on FOLD. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price target for the company. Bank of America raised their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. boosted their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. Finally, Morgan Stanley reduced their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.